High-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations

Size: px
Start display at page:

Download "High-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations"

Transcription

1 542431JBXXXX / Journal of Biomolecular ScreeningAlekseychyk et al. research-article2014 Original Research High-Throughput Screening and Stability Optimization of Anti-Streptavidin IgG1 and IgG2 Formulations Journal of Biomolecular Screening 2014, Vol. 19(9) Society for Laboratory Automation and Screening DOI: / jbx.sagepub.com Larysa Alekseychyk 1, Cheng Su 2, Gerald W. Becker 1, Michael J. Treuheit 1, and Vladimir I. Razinkov 1 Abstract Selection of a suitable formulation that provides adequate product stability is an important aspect of the development of biopharmaceutical products. Stability of proteins includes not only resistance to chemical modifications but also conformational and colloidal stabilities. While chemical degradation of antibodies is relatively easy to detect and control, propensity for conformational changes and/or aggregation during manufacturing or long-term storage is difficult to predict. In many cases, the formulation factors that increase one type of stability may significantly decrease another type under the same or different conditions. Often compromise is necessary to minimize the adverse effects of an antibody formulation by careful optimization of multiple factors responsible for overall stability. In this study, high-throughput stress and characterization techniques were applied to 96 formulations of anti-streptavidin antibodies (an IgG1 and an IgG2) to choose optimal formulations. Stress and analytical methods applied in this study were 96-well plate based using an automated liquid handling system to prepare the different formulations and sample plates. Aggregation and clipping propensity were evaluated by temperature and mechanical stresses. Multivariate regression analysis of high-throughput data was performed to find statistically significant formulation factors that alter measured parameters such as monomer percentage or unfolding temperature. The results of the regression models were used to maximize the stabilities of antibodies under different formulations and to find the optimal formulation space for each molecule. Comparison of the IgG1 and IgG2 data indicated an overall greater stability of the IgG1 molecule under the conditions studied. The described method can easily be applied to both initial preformulation screening and late-stage formulation development of biopharmaceutical products. Keywords biopharmaceuticals, high-throughput method, formulation screening, aggregation propensity, design of experiment, drug development, manufacturability, protein characterization Introduction In modern biopharmaceutical development, it is critical to decide on a stable formulation for the drug product as early in the development process as possible. Indeed, a stable formulation is needed in preclinical development or during candidate selection to ensure that the molecules being assessed do not degrade during storage prior to testing or during the testing itself. Normally, formulation development is a part of early or late-stage clinical development when one lead candidate has already been selected. With the wide range of ph, buffer compositions, and excipients available, the number of combinations of those factors is immense. Screening of even a subset of possible formulations during a typical development process requires a large amount of material, a lot of time, and other resources. Often the first available, somewhat stable formulation is chosen to move the product into clinical trials. Usually such a selection is supported by only one or two stress conditions and by only a few analytical methods. Often formulation factors that are favorable for one output (e.g., thermal stability) are not good for another, such as colloidal stability. Low ph 1 Process & Product Development, Amgen, Inc., Seattle, WA, USA 2 Biostatistics, Amgen, Inc., Seattle, WA, USA Received Mar 25, 2014, and in revised form May 23, Accepted for publication Jun 5, Supplementary material for this article is available on the Journal of Biomolecular Screening Web site at Corresponding Author: Vladimir I. Razinkov, Amgen, Inc., 1201 Amgen Court West, Seattle, WA 98119, USA. razinkov@amgen.com

2 Alekseychyk et al induces protein unfolding and aggregation, 1 but at the same time, the lower ph values minimize self-association caused by protein-ion interactions. 2 The presence of salt could be a critical factor for aggregation propensity, but it also affects stability differently depending on the ph of the solution. 3 5 Salt bridges can decrease the viscosity of some antibodies at high concentrations, 6,7 but at the same time they can also decrease conformational stability. A given excipient can be favorable for stability under one condition and unfavorable under other conditions, 8 and also mixtures of excipients can have their positive or negative effects. It is difficult to thoroughly evaluate a multitude of factors in one set of stability studies performed using typical low-throughput procedures. A large number of factors dictate application of preliminary experimental design for multiple samples and careful statistical analysis of a large number of data points. Recently, the concept of design of experiment (DOE) has been widely used in formulation development. 9 A DOE approach not only decreases the number of experiments to be performed but also creates the platform for data analysis. To establish correlations between factors and the stability of proteins, different statistical methods have been implemented. 10,11 With the recent advancements in automation and computer science, high-throughput methods could be automated to create a continuous process starting from sample preparation through data collection and analysis. Recently, researchers from Novartis Pharma AG constructed a custom-designed automated platform for formulation screening 12 and used it to collect data on several antibodies and many formulation conditions. The results were also compared with classic approaches and were found comparable. In another example of work with high-throughput methods, scientists from Merck, Inc. screened formulations of three antibodies for aggregation propensity and thermal stability under increased temperatures. 13 In both studies, microplates were used to store antibody formulations under the stress conditions and to place the samples into different instruments for measurements. Here we report an extension of that work where we employ 96-well microtiter plates as the platform carrier for formulation screening under stress conditions using the analytical methods of differential scanning fluorimetry (DSF) to assess conformational stability and size exclusion chromatography (SEC) to measure self-association. These are the first two of multiple analytical methods being developed for this high-throughput platform. The main purpose of this study was not to discover new properties of antibody formulations but rather to present the successful application of the high-throughput platform starting from automatic sample preparation, followed by highthroughput analytical assays and completed by thorough data analysis. With the help of statistical analysis, we have established correlations or the lack thereof between protein stability and formulation factors. Furthermore, we were able to distinguish the difference between IgG1 and IgG2 subtypes of the same antibody in stability responses to stress and formulation components. Such techniques can be easily complemented by or combined with other methods for full property screening, including colloidal stability and chemical stability, of biopharmaceutical products. Materials and Methods Monoclonal Antibody Formulation Preparation Anti-streptavidin IgG1 and IgG2 monoclonal antibodies were purified from mammalian cell culture and were dialyzed into buffer containing 20 mm sodium acetate at ph 5.2. The dialysis was performed at a 1:100,000 volume ratio at 4 C, including three buffer changes. The dialyzed protein was concentrated to ~50 mg/ml by centrifugation using 10,000 MWCO centrifugal filters (Amicon Ultra-15; Millipore Corporation, Billerica, MA). Excipient stock solutions such as sucrose, sorbitol, proline, and sodium chloride were prepared in water at high molar concentrations. All stock formulations and protein solutions were prepared in plastic vials and placed onto a TECAN (Männedorf, Switzerland) liquid handling system platform for further automated mixing. The final formulation compositions were created in two 48-well plates of 3 ml per well volume using a TECAN script. Then formulations were distributed by appropriate volume into 96-well plates assigned for stress or analytical assays. Separate plates were prepared for each time point and for each stress condition. The plates were hard-shell, full-skirted 96-well PCR plates (cat. HSP-9601; BioRad Laboratories, Hercules, CA). The following excipients were used: sucrose (lot C26H07; J. F. Baker, Columbus, OH), D-sorbitol (lot 075K0078; Sigma-Aldrich, St. Louis, MO), and L-proline (lot MKBH7930V; Sigma-Aldrich). The concentration of acetate, citrate, and phosphate buffers was 10 mm. The final concentration was 270 mm for each excipient, 0.001% for polysorbate (Tween 20) and 100 mm for NaCl. Differential Scanning Fluorimetry DSF measurements were performed according to the previously developed method. 14 Protein formulations were added to a 96-well plastic microplate at 19.0 µl per well. SYPRO Orange dye (Invitrogen, Carlsbad, CA) was diluted (1:250 dilution of stock) in water, and 1 µl of the diluted dye was added to each well, making the final dilution 1:5000. DSF measurements were made using a Bio-Rad CFX96 thermal cycler platform instrument (Bio-Rad Laboratories). The fluorescence of the dye during protein melting was monitored using the FRET mode while the temperature was increased from 20 C to 95 C at 0.1 C increments. Samples were equilibrated at each temperature for 3 s before taking the fluorescence readings. The fluorescence signal was then

3 1292 Journal of Biomolecular Screening 19(9) plotted as a function of temperature, and the temperature of hydrophobic exposure, T h, was determined as the midpoint of the lowest temperature transition from the first derivative plot as determined by the CFX Manager software (Bio-Rad Laboratories). Mechanical Agitation Stress The 96-well plates with antibody formulations were sealed and mechanical agitation stress was applied using an orbital shaker (MixMate Orbital Shaker; Eppendorf North America, Hauppauge, NY) according to the method described as follows: each 96-well round-bottom plate containing 200 µl per well of the sample formulation solution was sealed and shaken at 4 C for 24 h at a constant speed of 2000 rpm. After agitation, plates were centrifuged at 3000 rpm to sediment large insoluble particles, and the supernatant was transferred to another plate for analysis. High-Throughput Size Exclusion Chromatography The amount of soluble mab oligomer present in each formulation was analyzed by high-throughput SEC. The method employed a Waters Acquity H-class UPLC system (Waters Corporation, Milford, MA) equipped with a UV diode array detector. Then, 10 µg of each sample was injected onto a single gel filtration column (ACQUITY UPLC BEH200 SEC 1.7 µm, mm; Waters Corporation) with a mobile phase containing 100 mm sodium phosphate and 250 mm sodium chloride (ph 6.8) at a flow rate of 0.4 ml/min and a runtime of 6 min. The results were analyzed using Empower software (Waters Corporation), and the peak integration was calculated using the UV absorbance at 280 nm. The results were reported as monomer peak percentage of total integrated area. Data Analysis and Interpretation Both continuous and categorical variables were included in the experimental design, ph as a continuous variable and buffer, excipients, and detergent as categorical variables. There were 96 results from each experiment for all combinations of formulation conditions. An example of using such a design approach has been shown in our previous report. 15 The statistical software package JMP 7.02 and Proc GLM in SAS version 9.3 (SAS Institute, Inc., Cary, NC) were used for the calculations. The method of standard least squares with emphasis on effect screening was used in the regression models for data fitting. The modeling process starts with a regression model consisting of the main effects of factors along with their two-way interactions and a quadratic term for ph values. Scaled estimates were used to compare the effects of different formulation factors. Observations were considered outliers and excluded if the absolute values of their model Studentized residuals were greater than 2. After data exclusion, the modeling would then repeat, and a list of significant model terms (p < 0.05) was selected for the final model. The regression model was used to predict response values for given factor values. Based on the model, a prediction formula was created and a graph representing values obtained by experiment versus predicted values was plotted for both T h and percentage of monomer. The deviation of such a fit from the linear model was characterized by R 2 values. Results and Discussion Thermostability Screening by DSF DSF was used to determine the temperature of hydrophobic exposure, T h, of 96 formulation conditions. The T h is an approximation of the unfolding or melting temperature, T m, often determined by differential scanning calorimetry (DSC) for monoclonal antibodies. 14,16 Results of the determination of T h for each of the 96 formulations are shown in Table 1A,B. For both IgG1 (Table 1A) and IgG2 (Table 1B), the effect of ph was very visible. T h values appeared to be significantly lower than that for higher ph. The addition of proline increased the thermostability at ph 3.5, but proline slightly decreased T h values for formulations at higher ph, where sucrose had a positive effect. The T h values for an IgG2 were lower than for an IgG1 in the same formulations, as shown in Table 1C, where the differences between the T h values for IgG1 and IgG2 were calculated for each formulation on the plate. The IgG1 molecule appeared to be more stable, especially in formulations with salt at low ph. A thorough analysis of the effects of formulation factors was performed by the application of multivariable statistical analysis, as described in the Materials and Methods. The statistical significance of each formulation factor can be used to determine whether the effect on T h was real or due to random variation. First, the goodness of the model was assessed by plotting the experimental data versus the data predicted by our regression models. As shown in Figure 1A,B, the fits had high R 2 values of for both the IgG1 and IgG2 molecules (i.e., roughly 99% of the variation in the T h response is explained by the corresponding model). To estimate the significance of the formulation factors, we used corresponding scaled estimates, which represented the positive or negative effect on thermostability and its relative magnitude in the predictive regression model. The significance of the factors was determined by the p value. A p value of 0.05 or less for the factor was considered statistically significant (see Materials and Methods). In the table inserted into Figure 1, scaled estimates are presented for all statistically significant factors and their interactions. The most significant factor was ph and the term ph*ph, creating the curvature on T h response versus ph values. Our

4 Alekseychyk et al Table 1. T h Values Determined by Differential Scanning Fluorimetry for (A) IgG1 and (B) IgG2 Anti-Streptavidin Molecules, with the (C) Difference between IgG1 and IgG2 T h Values. NaCl Without NaCl Tween 20 Without Tween 20 Tween 20 Without Tween 20 Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline A ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F B ph 6.0 G ph 8.0 H ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F C ph 6.0 G ph 8.0 H ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F ph 6.0 G ph 8.0 H The darkest shading represents the lowest values.

5 1294 Journal of Biomolecular Screening 19(9) Figure 1. Experimentally determined T h values plotted against the predicted T h for IgG1 (A) and IgG2 (B) anti-streptavidin molecules. The design of experiment procedure and statistical analysis are described in the Materials and Methods. (C) T h dependence on ph for anti-streptavidin molecules predicted by multivariate analysis of differential scanning fluorimetry data (see Materials and Methods). The results are shown for IgG1 (star, diamond), IgG2 (circle, square), acetate buffer (star, circle), and phosphate buffer (diamond, square); formulations without salt, open symbols; formulations with salt, filled symbols. Dashed lines = extrapolated data. All data are shown for formulation without detergent and with proline as an excipient. Inserted table shows R 2 and scaled estimates for the prediction model. results are consistent with a previously observed increase of unfolding temperature at higher ph. 17 The buffer type is also significant with phosphate presence as a negative factor and citrate or acetate presence as positive factors. According to Figure 1, the presence of salt is also a significant negative factor (see also Table 1A,B). Some interactions of ph, buffer, and salt factors are important in the model. Based on the presented data, the best thermally stable formulation for both IgGs would be acetate or citrate at ph , with no salt. At this range of ph values, sucrose and sorbitol make better excipients than does proline. But if antibody formulations are exposed to low ph, proline definitely helps to increase thermostability of the IgG molecule. Considering all significant factors in the model, we plotted a prediction function of T h versus ph for both IgG1 and IgG2 in different formulations (see Fig. 1C) according to the described model. The data are shown for acetate and phosphate buffers with and without salt. Extrapolated values, covering the ph range where experimental data were not taken, are indicated by the dashed lines. The curves for citrate buffer fell between the curves for acetate and phosphate and are not shown. The effects of excipients were not significant, and graphs without detergent, with only proline, are shown. According to Figure 1C, maximum thermostability was predicted in the range of ph for acetate buffer and in the range of ph for phosphate buffer. The presence of salt decreased T h, and this effect was more significant at low ph. Salt also shifted the T h prediction to a higher ph. By this analysis, IgG1 was predicted to be more stable than IgG2. The difference between T h values for IgG1 and IgG2 was the greatest at low ph, becoming virtually nonexistent at ph >6.0. Statistical analysis has presented a complete picture of thermostability of both IgG1 and IgG2 molecules in 96 formulations. We determined the significant formulation factors and predicted the T h dependence on them with a high level of linearity between actual and predicted values. Using a prediction model, we can select formulations with the maximum thermal stability. According to our analysis, formulations with ph around the range of and with no salt are more stable in acetate buffer. Excipients and detergent are not significant for thermostability in that ph range. Formulations in phosphate buffer have higher thermostability at ph ~ without salt. These results are in good correlation with previously published studies on the conformational stability of monoclonal antibodies. 18,19 A good correlation has been found between the temperature of unfolding and aggregation propensity. 20 Other works focused on the general dependencies of protein aggregation mechanisms and conformational stability. Several mechanisms have been proposed to relate aggregation and unfolding. 21,22 Stability at Different Temperatures The samples were incubated at different temperatures for 2 weeks, and the monomer percentage was determined by SEC. Monomer percentage values from SEC for all formulations and temperatures are presented in Table 2 for IgG1 and in Table 3 for IgG2. For the scaled estimates obtained by regression models from SEC results and for representative SEC chromatograms after incubation at different temperatures, see the Supplemental Data.

6 Alekseychyk et al Incubation of an IgG1 and an IgG2 at 4 C in the 96 different formulation conditions showed little degradation for IgG1 when analyzed by SEC (Table 2A). Data for IgG2 (Table 3A) showed more degradation in general for all samples and specifically at ph 3.5 in both acetate and citrate buffers. Also, citrate buffer seemed to decrease stability in comparison with acetate and phosphate buffers. A more thorough analysis by multivariate regression of the SEC IgG1 and IgG2 data showed poor prediction models. This lack of correlation can be simply explained by the low level of degradation at 4 C. Similar to the results from the 4 C study, there was no visible correlation of degradation with formulation factors for the IgG1 and IgG2 samples after 25 C incubation by using SEC results (Tables 2B and 3B). The samples in citrate buffer and at ph 3.5 were less stable. The results obtained by SEC after incubation at 25 C showed no acceptable prediction model for the IgG1 molecule. But the model for the IgG2 had a better prediction power, and the effect of formulation factors on the IgG2 samples was much more pronounced at 25 C than at 4 C. Incubation at 40 C. At the highest incubation temperature, some samples were almost completely degraded. According to the SEC data in Tables 2C and 3C, the samples without salt at ph 3.5 had a low percentage of monomer, and this effect was more pronounced than for the 4 C incubation data. In fact, for IgG2 samples, there was no more than 7% of monomer left in the citrate buffer at these conditions. The positive effect of proline on stability at ph 3.5 was clear for IgG1 samples with salt and IgG2 samples in citrate without salt. IgG2 samples with salt were degraded to the level where proline could no longer help. As expected, at high temperature, there were more degradation and more significant factors (see Supplemental Data). According to the SEC-based model, the most significant single factors were ph and its square term ph*ph, with the higher values for the IgG2 molecule. In the analysis, types of buffers were significant factors for IgG2 and, with the exception of acetate buffer, also for IgG1. Among excipients, only the presence of proline significantly increased monomer percentage in the SEC samples for IgG1. Salt was a negative factor, with comparable values for IgG1 and IgG2 molecules. Stability after Mechanical Agitation Mechanical agitation is another stress to test the stability of formulations under conditions of induced protein exposure to a liquid-air interface. Results shown in Table 4 indicate good stability of IgG1 samples with the range of monomer percentage values from 96.9 to There was no visible dependence on formulation conditions. IgG2 results showed a decrease in monomer percentage in the samples at low ph and in the presence of salt. The absence of detergent also decreased the stability of agitated samples. Statistical analysis produced relatively weak prediction models, indicating low correlations of SEC data with formulation factors. Only IgG2 results provided a good prediction for a positive effect for acetate and a negative one for phosphate. Increased ph values and the presence of detergent slightly increased formulation stability for IgG2. Optimization of Formulations and Comparison of IgG Molecules The choice of the best formulation conditions depends on many factors. In our study, we have obtained results from several analytical and stress techniques. We have determined significant factors affecting the stability of samples under temperature and mechanical stresses. If we would have used the classic way to pick the most stable formulations, we would have looked for the samples with maximum monomer percentage for each data set. Depending on what component of stability we would prefer to maximize, we choose the best formulations from the available data. But sometimes, the high values for monomer percentage correspond to different conditions. It is obvious that a more systematic analysis is necessary to find the optimal combination of factors for a stable formulation. Correlation between T h data and SEC results after incubation at high temperature. A good prediction model, with dependence on multiple formulation factors, was obtained for the T h values determined by DSF. An interesting question, then, is, How well can T h predict degradation, presumably aggregation, after exposure to high temperature? To answer this question, we examined the SEC data set that provided monomer percentage after the 40 C incubation. In Figure 2A, the monomer amount (SEC data) was plotted as a function of T h (DSF data) for both IgG1 and IgG2 molecules in all formulations studied. It seems reasonable that if the incubation temperature is much lower than the T h value, the aggregation propensity depends on factors other than conformational stability. 23,24 As shown in previous studies, 25 the unfolding transition of the CH2 domain overlaps with the unfolding of the Fab domain at ph ~5.0, which makes DSF measurements less sensitive. Since ph is the major factor affecting DSF data, formulations with higher T h are more stable after incubation at 40 C. The closer the unfolding temperature is to the incubation temperature, the higher the aggregation level. After the T h value reaches some distance from the incubation temperature, aggregation drops significantly (see Fig. 2A). But protein aggregation caused by elevated temperature could be dependent on not only conformational stability. 19 Therefore, to accurately predict aggregation propensity, one should consider

7 1296 Journal of Biomolecular Screening 19(9) Table 2. Monomer Percentage Values Determined by Size Exclusion Chromatography for IgG1 Anti-Streptavidin Molecule after Incubation at (A) 4 C, (B) 25 C, and (C) 40 C. NaCl Without NaCl Tween 20 Without Tween 20 Tween 20 Without Tween 20 Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline A ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F B ph 6.0 G ph 8.0 H ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F C ph 6.0 G ph 8.0 H ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F ph 6.0 G ph 8.0 H The darkest shading represents the lowest values.

8 Alekseychyk et al Table 3. Monomer Percentage Values Determined by Size Exclusion Chromatography for IgG2 Anti-Streptavidin Molecule after Incubation at (A) 4 C, (B) 25 C, and (C) 40 C. NaCl Without NaCl Tween 20 Without Tween 20 Tween 20 Without Tween 20 Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline A ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F B ph 6.0 G ph 8.0 H ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F C ph 6.0 G ph 8.0 H ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F ph 6.0 G ph 8.0 H The darkest shading represents the lowest values. Incubation at 4 C and 25 C.

9 1298 Journal of Biomolecular Screening 19(9) Table 4. Monomer Percentage Values Determined by Size Exclusion Chromatography for (A) IgG1 and (B) IgG2 Anti-Streptavidin Molecules after Agitation at 4 C. NaCl Without NaCl Tween 20 Without Tween 20 Tween 20 Without Tween 20 Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline Sucrose Sorbitol Proline A ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F ph 6.0 G ph 8.0 H B ph 3.5 A ph 5.2 B ph 6.0 C ph 3.5 D ph 5.2 E ph 6.0 F ph 6.0 G ph 8.0 H The darkest shading represents the lowest values. all factors affecting protein-protein and protein-solution interactions, including chemical, colloidal, and conformational stabilities. 22,26,27 Maximizing formulation stability with the help of prediction models. In these studies, two types of assays probing conformational stability as well as stability under mechanical stress were employed. Using the results of these studies, prediction models were developed from the SEC results under each stress condition. This provides an opportunity to determine the optimal formulation conditions under which the monomer content is maximized. The models obtained for the two IgG types under stress conditions had a different goodness of fit characterized by the linearity (root mean square error value: R 2 ) of the actual versus predicted value plot. The R 2 value for the 4 C incubation was low for both IgG1 and IgG2. The highest R 2 was obtained for the 40 C incubation. R 2 values for SEC models were higher for the IgG2 than for IgG1 molecules after both temperature and mechanical stress, reflecting the fact that the IgG2 was less stable and more dependent on formulation factors. To evaluate stability dependence on formulation factors at 40 C, we applied the same procedure as we used for constructing a prediction model based on the DSF results. We used the monomer amount determined by SEC as a major output value of

10 Alekseychyk et al stability. Multivariate regression analysis was performed to obtain a prediction formula for monomer amount versus formulation factors dependence. In Figure 2B,C, this function is plotted with ph as the x-axis variable factor for the IgG2 molecule in acetate, citrate, and phosphate buffers in the presence of salt and without salt. The excipients were not significant factors in our model with the exception of proline for IgG1, and we selected proline as a factor for the plots shown in Figure 2B,C. Similar to the DSF-based model, the results beyond the experimental conditions are represented by dashed lines. According to the predicted function, the maximum monomer content was reached at ph 5.1 for acetate buffer without salt. The addition of salt shifted the maximum slightly to ph 5.4. For the citrate buffer, the maximum was at ph 6.0 without salt and at ph 5.7 with salt and, at low ph with salt, made the citrate formulations slightly more stable. Formulations in phosphate buffer showed maximum stability at ph 6.5 without salt and at ph 7.3 in the presence of salt. At higher ph, the presence of salt stabilized phosphate formulations. To compare IgG1 and IgG2 molecules, we prepared plots for both acetate and phosphate buffers with and without salt (see Fig. 2C). IgG1 formulations were more stable than were IgG2 formulations at low ph in acetate with no salt and at higher ph in phosphate with salt. In other formulations, the differences were not significant for the studied experimental conditions, but the prediction model showed theoretically higher IgG1 stability for citrate formulations with salt, and for phosphate formulations without salt, the stability was higher for the IgG2. As can be seen in Figure 2B,C, the prediction function monomer amount versus ph was dependent on the type of buffer and the presence of salt. Formulations at low ph were unstable because of low conformational stability. The presence of salt in combination with low ph values increased antibody instability even more. The maximum monomer amount shifted at different ph values in different buffers. Salt shifted the maximum to higher ph in acetate and phosphate buffers. For citrate buffer, the shift with salt went to slightly lower ph values. Generally, the proteins were more soluble when the solution ph was far from the proteins pi. 28 For the anti-streptavidin IgG1 and IgG2 isotypes, the theoretical pi values were 8.2 and 7.7, respectively. Mechanical agitation stress did not have a significant impact on IgG1 monomer content, changing by no more than 3% as analyzed by SEC. In turn, the IgG2 molecule was more sensitive to agitation stress and showed greater degradation at higher ph in phosphate buffer. Based on the systematic analysis illustrated here, using both experimental data and prediction models, we can select the most stable formulations for IgG1 and IgG2 molecules. According to our data, antibodies are significantly degraded at ph 3.5 at elevated temperatures. Our models predict some curvature in the dependence of both thermostability and monomer content on ph with the maxima for each located between the high and low ph values (see Fig. 1 and Fig. 2B,C). Figure 2. (A) The plot of monomer amount (from size exclusion chromatography [SEC] data) versus T h (from differential scanning fluorimetry [DSF] data). SEC results were obtained after incubation of IgG1 (triangles) and IgG2 (filled circles) formulation samples at 40 C for 2 weeks. (B) Predicted functions for anti-streptavidin IgG2 monomer amount obtained by SEC and plotted against ph. The functions are presented for acetate (circles), citrate (triangles), and phosphate (squares) buffers in the presence (filled symbols) and absence (open symbols) of salt. The dashed line indicates ph range beyond experimental conditions for particular function. (C) Predicted functions for anti-streptavidin monomer amount plotted against ph. The functions are presented for acetate (circles and stars) and phosphate (squares and diamonds) buffers in the presence (filled symbols) and absence (open symbols) of salt for IgG1 (stars and diamonds) and IgG2 (circles and squares).

11 1300 Journal of Biomolecular Screening 19(9) Formulations with phosphate buffer resulted in strong negative effect for both IgG1 and IgG2 antibodies after a 40 C incubation (see Tables 2 and 3). Although high ph values seem to be favorable for thermal stability and for monomer content after high temperature exposure, the proximity of ph to pi might compromise colloidal stability and increase native aggregation propensity. This is confirmed for the IgG2 molecule by the agitation study (see Table 4). buffer appears more preferable than citrate in stability models at all temperatures and after agitation stress. The presence of detergent increases stability after agitation but makes no difference under high temperature stress. Proline is desirable under very stressful conditions, such as high temperature in low ph formulations in the presence of salt; however, sucrose provides greater stability at higher ph values, which are more common for antibody formulations. Considering all factors, the recommendation for the best formulation for IgG1 and IgG2 is acetate buffer, ph , with detergent and sucrose and without salt. In this study, high-throughput methods of stress and characterization analysis for screening a large number of formulations, consuming only a small amount of protein, were applied to determine formulation conditions under which a studied protein was most stable. The choice of a final formulation can be dependent on many parameters, and the analysis of high-throughput data provides an opportunity to select the desired stability output according to formulation factors and their values. In this work, we used only temperature and mechanical agitation as stress conditions; however, new stresses and analytical techniques can easily be integrated into the package of assays described here. Formulation screening can also be performed by sequential steps, screening a wide range of conditions followed by a higher resolution analysis with a focus on only one factor. The modular structure of this method and its flexibility allow a seamless adaptation and application to every stage of the drug development process, from candidate selection to commercial formulation development. Acknowledgments We thank Dr. R. Matthew Fesinmeyer for discussions regarding the agitation methods, Dr. Ramil Latypov for discussion regarding conformational stability, and Dr. Gerd Kleemann and Dr. Bruce Kerwin for discussions of high-throughput assays. Declaration of Conflicting Interests The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article. Funding The authors received no financial support for the research, authorship, and/or publication of this article. References 1. Kendrick, B. S.; Cleland, J. L.; Lam, X.; et al. Aggregation of Recombinant Human Interferon Gamma: Kinetics and Structural Transitions. J. Pharm. Sci. 1998, 87, He, F.; Joshi, S. B.; Bosman, F.; et al. Structural Stability of Hepatitis C Virus Envelope Glycoprotein E1: Effect of ph and Dissociative Detergents. J. Pharm. Sci. 2009, 98, Wang, T.; Kumru, O. S.; Yi, L.; et al. Effect of Ionic Strength and ph on the Physical and Chemical Stability of a Monoclonal Antibody Antigen-Binding Fragment. J. Pharm. Sci. 2013, 102, Rubin, J.; Linden, L.; Coco, W. M.; et al. Salt-Induced Aggregation of a Monoclonal Human Immunoglobulin G1. J. Pharm. Sci. 2013, 102, Arosio, P.; Jaquet, B.; Wu, H.; et al. On the Role of Salt Type and Concentration on the Stability Behavior of a Monoclonal Antibody Solution. Biophys. Chem. 2012, , Liu, J.; Nguyen, M. D.; Andya, J. D.; et al. Reversible Self-Association Increases the Viscosity of a Concentrated Monoclonal Antibody in Aqueous Solution. J. Pharm. Sci. 2005, 94, Guo, Z.; Chen, A.; Nassar, R. A.; et al. Structure-Activity Relationship for Hydrophobic Salts as Viscosity-Lowering Excipients for Concentrated Solutions of Monoclonal Antibodies. Pharm. Res. 2012, 29, Baynes, B. M.; Wang, D. I.; Trout, B. L.; et al. Role of Arginine in the Stabilization of Proteins against Aggregation. Biochemistry 2005, 44, Awotwe-Otoo, D.; Agarabi, C.; Wu, G. K.; et al. Quality by Design: Impact of Formulation Variables and Their Interactions on Quality Attributes of a Lyophilized Monoclonal Antibody. Int. J. Pharm. 2012, 438, He, F.; Woods, C. E.; Becker, G. W.; et al. High-Throughput Assessment of Thermal and Colloidal Stability Parameters for Monoclonal Antibody Formulations. J. Pharm. Sci. 2011, 100, Anurag, S.; Winkle, R.; Winkle, H. Quality by Design for Biopharmaceuticals. Nat. Biotech. 2009, 27, Zhao, H.; Graf, O.; Milovic, N.; et al. Formulation Development of Antibodies Using Robotic System and High- Throughput Laboratory (HTL). J. Pharm. Sci. 2010, 99, Li, Y.; Mach, H.; Blue, J. T. High Throughput Formulation Screening for Global Aggregation Behaviors of Three Monoclonal Antibodies. J. Pharm. Sci. 2011, 100, He, F.; Hogan, S.; Latypov, R. F.; et al. High Throughput Thermostability Screening of Monoclonal Antibody Formulations. J. Pharm. Sci. 2010, 99, He, F.; Woods, C. E.; Trilisky, E.; et al. Screening of Monoclonal Antibody Formulations Based on High- Throughput Thermostability and Viscosity Measurements: Design of Experiment and Statistical Analysis. J. Pharm. Sci. 2011, 100, Goldberg, D. S.; Bishop, S. M.; Shah, A. U.; et al. Formulation Development of Therapeutic Monoclonal Antibodies Using High-Throughput Fluorescence and Static Light Scattering

12 Alekseychyk et al Techniques: Role of Conformational and Colloidal Stability. J. Pharm. Sci. 2011, 100, Vermeer, A. W.; Norde, W. The Thermal Stability of Immunoglobulin: Unfolding and Aggregation of a Multi- Domain Protein. Biophys. J. 2000, 78, Ejima, D.; Tsumoto, K.; Fukada, H.; et al. Effects of Acid Exposure on the Conformation, Stability, and Aggregation of Monoclonal Antibodies. Proteins 2007, 66, Saito, S.; Hasegawa, J.; Kobayashi, N.; et al. Effects of Ionic Strength and Sugars on the Aggregation Propensity of Monoclonal Antibodies: Influence of Colloidal and Conformational Stabilities. Pharm. Res. 2013, 30, Brummitt, R. K.; Nesta, D. P.; Chang, L.; et al. Nonnative Aggregation of an IgG1 Antibody in Acidic Conditions: Part 1. Unfolding, Colloidal Interactions, and Formation of High- Molecular-Weight Aggregates. J. Pharm. Sci. 2011, 100, Kim, N.; Remmele, R. L., Jr.; Liu, D.; et al. Aggregation of Anti-Streptavidin Immunoglobulin Gamma-1 Involves Fab Unfolding and Competing Growth Pathways Mediated by ph and Salt Concentration. Biophys. Chem. 2013, 172, Thakkar, S. V.; Sahni, N.; Joshi, S. B.; et al. Understanding the Relevance of Local Conformational Stability and Dynamics to the Aggregation Propensity of an IgG1 and IgG2 Monoclonal Antibodies. Protein Sci. 2013, 22, Banks, D. D.; Latypov, R. F.; Ketchem, R. R.; et al. Native- State Solubility and Transfer Free Energy as Predictive Tools for Selecting Excipients to Include in Protein Formulation Development Studies. J. Pharm. Sci. 2012, 101, Chou, D. K.; Krishnamurthy, R.; Manning, M. C.; et al. Physical Stability of Albinterferon-α(2b) in Aqueous Solution: Effects of Conformational Stability and Colloidal Stability on Aggregation. J. Pharm. Sci. 2012, 101, Ionescu, R. M.; Vlasak, J.; Price, C.; et al. Contribution of Variable Domains to the Stability of Humanized IgG1 Monoclonal Antibodies. J. Pharm. Sci. 2008, 97, Latypov, R. F.; Hogan, S.; Lau, H.; et al. Elucidation of Acid-Induced Unfolding and Aggregation of Human Immunoglobulin IgG1 and IgG2 Fc. J. Biol. Chem. 2012, 287, Hari, S. B.; Lau, H.; Razinkov, V. I.; et al. Acid-Induced Aggregation of Human Monoclonal IgG1 and IgG2: Molecular Mechanism and the Effect of Solution Composition. Biochemistry 2010, 49, Shaw, K. L.; Grimsley, G. R.; Yakovlev, G. I.; et al. The Effect of Net Charge on the Solubility, Activity, and Stability of Ribonuclease Sa. Protein. Sci. 2001, 10,

When proteins are being developed as therapeutics, an important consideration is both the inherent conformational

When proteins are being developed as therapeutics, an important consideration is both the inherent conformational Using Differential Scanning Calorimetry in Understanding the Correlation Between Thermal Stability and Protein Stability: A Case Study Written by Jie Wen, Yijia Jiang, Kathryn Hymes*, Ke Gong*, and Linda

More information

AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis

AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis Application Note Biologics Development AdvanceBio HIC: a Hydrophobic HPLC Column for Monoclonal Antibody (mab) Variant Analysis Using the Agilent 16 Infinity II Bio-Inert LC Authors Andrew Coffey and Sandeep

More information

Application Note. Authors. Abstract. Biopharmaceuticals

Application Note. Authors. Abstract. Biopharmaceuticals Characterization of monoclonal antibodies on the Agilent 126 Infinity Bio-inert Quaternary LC by Size Exclusion Chromatography using the Agilent BioSEC columns Application Note Biopharmaceuticals Authors

More information

Characterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system

Characterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system Characterization of mab aggregation using a Cary 60 UV-Vis Spectrophotometer and the Agilent 1260 Infinity LC system Application Note Biopharmaceuticals Authors Arunkumar Padmanaban and Sreelakshmy Menon

More information

A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies

A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies A Comprehensive Workflow to Optimize and Execute Protein Aggregate Studies Combining Size Exclusion Chromatography with Method Development and Light Scattering Application Note Biotherapeutics and Biosimilars

More information

SEC/CEX - separation of biomolecules: High-throughput screening (HTS) and data analysis via platform methods

SEC/CEX - separation of biomolecules: High-throughput screening (HTS) and data analysis via platform methods SEC/CEX - separation of biomolecules: High-throughput screening (HTS) and data analysis via platform methods Kerstin Appenzeller Kathrin Schäker-Theobald, PhD 20. Juni 2018 1 Disclosure Kerstin Appenzeller

More information

Off to the races: rapid buffer exchange, protein quantification and stability screening with Junior, Lunatic and Uncle

Off to the races: rapid buffer exchange, protein quantification and stability screening with Junior, Lunatic and Uncle Application Note Off to the races: rapid buffer exchange, protein quantification and stability screening with Junior, Lunatic and Uncle Introduction The conformational, chemical and colloidal stability

More information

Prometheus Series Product Information

Prometheus Series Product Information Prometheus Series Product Information Prometheus Instruments for nanodsf www.nanotemper-technologies.com Prometheus Series NanoTemper Technologies offers nanodsf technology with the Prometheus Series.

More information

Application Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider

Application Note. Author. Abstract. Biopharmaceuticals. Verified for Agilent 1260 Infinity II LC Bio-inert System. Sonja Schneider Combining small-scale purification and analysis of monoclonal antibodies on one instrument Protein purification with high-volume injection using the Agilent 126 Infinity Bio-inert Quaternary LC System

More information

Mobile Phase Optimization in SEC Method Development

Mobile Phase Optimization in SEC Method Development Application Note Pharma & Biopharma Mobile Phase Optimization in SEC Method Development Author Richard Hurteau Agilent Technologies, Inc., Wilgton, DE, USA Abstract Aggregation of monoclonal antibody (mab)

More information

Separating proteins with activated carbon

Separating proteins with activated carbon Separating proteins with activated carbon Matthew T. Stone and Mikhail Kozlov EMD Millipore Corp. 80 Ashby Road, Bedford, MA 01730, USA Supporting Information Supporting information for Figure 1 Experimental

More information

Polishing of monoclonal antibodies using Capto S ImpAct

Polishing of monoclonal antibodies using Capto S ImpAct Application note 29-83-27 AA Ion exchange chromatography Polishing of monoclonal antibodies using Capto S ImpAct Capto S ImpAct chromatography medium (resin) is a strong cation exchanger (CIEX). The medium

More information

mab Titer Analysis with the Agilent Bio-Monolith Protein A Column

mab Titer Analysis with the Agilent Bio-Monolith Protein A Column mab Titer Analysis with the Agilent Bio-Monolith Protein A Column Application Note Biopharmaceuticals and Biosimilars Authors Emmie Dumont, Isabel Vandenheede, Pat Sandra, and Koen Sandra Research Institute

More information

Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus

Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Developing Robust and Efficient IEX Methods for Charge Variant Analysis of Biotherapeutics Using ACQUITY UPLC H-Class System and Auto Blend Plus Robert Birdsall, Thomas Wheat, and Weibin Chen Waters Corporation,

More information

Lifetime stability of size exclusion chromatography columns for protein aggregate analysis

Lifetime stability of size exclusion chromatography columns for protein aggregate analysis APPLICATION NOTE 72362 Lifetime stability of size exclusion chromatography columns for protein aggregate analysis Authors Amy Farrell 1, Craig Jakes 1, Alexander Ley 2, Mauro De Pra 2, Frank Steiner 2,

More information

Formulation Optimization Using the HUNK

Formulation Optimization Using the HUNK Formulation Optimization Using the HUNK Application Note Measuring ΔG: The Development Pathway to the Optimal Drug Product The development of successful biologics requires formulations that extend shelf

More information

LabChip GXII: Antibody Analysis

LabChip GXII: Antibody Analysis WHITE PAPER LabChip GXII: Antibody Analysis Antibody Analysis using microfluidic technology in high throughput Quality by Design Experiments Abstract Current initiatives in Process Analytical Technology

More information

Molecular Characterization of Biotherapeutics The Agilent 1260 Infi nity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection

Molecular Characterization of Biotherapeutics The Agilent 1260 Infi nity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection Molecular Characterization of Biotherapeutics The Agilent 126 Infi nity Multi-Detector Bio-SEC Solution with Advanced Light Scattering Detection Application Note Biologics and Biosimilars Authors Sonja

More information

Summary of Article. Introduction

Summary of Article. Introduction FORMULATION AND DEVELOPMENT» Automated and Rapid Methods to Assess Quality & Stability of Biologics: Recent Developments and Practical Ways to Implement Them in Formulation Development Summary of Article

More information

Characterization of IgG monomers & their aggregates

Characterization of IgG monomers & their aggregates Characterization of IgG monomers & their aggregates A comparison between column calibration & multi-detection SEC PROTEIN AGGREGATION MOLECULAR SIZE MOLECULAR STRUCTURE MOLECULAR WEIGHT Introduction In

More information

Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs

Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs Best Practices in Formulation and Lyophilization Development Proteins, mabs and ADCs Best Practices in Formulation and Lyophilization Development The ultimate goal of formulation development is a stable

More information

Capacity and performance of MabSelect PrismA protein A chromatography resin

Capacity and performance of MabSelect PrismA protein A chromatography resin Capacity and performance of protein A chromatography resin is a protein A resin of which both the ligand and the base matrix have been optimized. The resin exhibits improved capacity over its predecessor

More information

Separation of Monoclonal Antibodies Using TSKgel HPLC Columns

Separation of Monoclonal Antibodies Using TSKgel HPLC Columns ANALYSIS S e p a r a t i o n R e p o r t N o. 7 4 Separation of Monoclonal Antibodies Using TSKgel HPLC Columns Table of Contents 1. Introduction 1 2. Separation Mode and Purification Method 1 3. Applications

More information

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns

High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns High-throughput and Sensitive Size Exclusion Chromatography (SEC) of Biologics Using Agilent AdvanceBio SEC Columns Agilent AdvanceBio SEC 3 Å, 2.7 µm columns Application note Bio-Pharmaceutical Author

More information

The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite

The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite The practical task of monoclonal IgG purification with CHT TM ceramic hydroxyapatite Pete Gagnon, Jie He, Paul Ng, Julia Zhen, Cheryl Aberin, Heather Mekosh 11th Annual Waterside Conference, Chicago, May

More information

FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC

FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC FORMULATION & LYOPHILIZATION CYCLE DEVELOPMENT OF AN ADC A Case Study Wendy Saffell-Clemmer Director, R&D Baxter BioPharma Solutions Antibody Drug Conjugates (ADCs) are complex molecules consisting of

More information

Validation of a Dual Wavelength Size Exclusion HPLC Method with Improved Sensitivity to Detect Aggregates of a Monoclonal Antibody Biotherapeutic

Validation of a Dual Wavelength Size Exclusion HPLC Method with Improved Sensitivity to Detect Aggregates of a Monoclonal Antibody Biotherapeutic Validation of a Dual Wavelength Size Exclusion HPLC Method with Improved Sensitivity to Detect Aggregates of a Monoclonal Antibody Biotherapeutic By J. Tompkins1, T. Spurgeon 1, R. Tobias 1, J. Anders1,

More information

High Throughput Sub-4 Minute Separation of Antibodies using Size Exclusion Chromatography

High Throughput Sub-4 Minute Separation of Antibodies using Size Exclusion Chromatography High Throughput Sub-4 Minute Separation of Antibodies using Size Exclusion Chromatography TSKgel APPLICATION NOTE Introduction Gel Filtration Chromatography (GFC) is a powerful analytical tool in the separation

More information

nanodsf 2bind: Your service provider for biophysical characterization of proteins Precisely revealing protein folding and stability

nanodsf 2bind: Your service provider for biophysical characterization of proteins Precisely revealing protein folding and stability nanodsf Precisely revealing protein folding and stability 2bind: Your service provider for biophysical characterization of proteins This booklet was written and designed by 2bind 08 2015 Any reproduction

More information

TECHNICAL BULLETIN. HIS-Select HF Nickel Affinity Gel. Catalog Number H0537 Storage Temperature 2 8 C

TECHNICAL BULLETIN. HIS-Select HF Nickel Affinity Gel. Catalog Number H0537 Storage Temperature 2 8 C HIS-Select HF Nickel Affinity Gel Catalog Number H0537 Storage Temperature 2 8 C TECHNICAL BULLETIN Product Description HIS-Select High Flow (HF) is an immobilized metal-ion affinity chromatography (IMAC)

More information

MST Starting Guide Monolith NT.115

MST Starting Guide Monolith NT.115 MST Starting Guide Monolith NT.115 Contents 1. How to design an experiment 2. Before you start 3. Assay Setup Pretests 4. Assay Setup 5. MST-experiment using temperature control 6. Data Interpretation

More information

High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography

High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography High-resolution Analysis of Charge Heterogeneity in Monoclonal Antibodies Using ph-gradient Cation Exchange Chromatography Agilent 1260 Infinity Bio-inert Quaternary LC System with Agilent Bio Columns

More information

ION EXCHANGE KIT FOR MAB SEPARATIONS

ION EXCHANGE KIT FOR MAB SEPARATIONS ION EXCHANGE KIT FOR MAB SEPARATIONS Sepax Technologies, Inc. 5 Innovation Way Newark, Delaware, USA Tel: (32) 366-111 Fax: (32) 366-1151 Toll free: www.sepax-tech.com Content Introduction... 1 Technical

More information

Multiple Detector Approaches to Protein Aggregation by SEC

Multiple Detector Approaches to Protein Aggregation by SEC Multiple Detector Approaches to Protein Aggregation by SEC Application Note BioPharma Author Andrew Coffey Agilent Technologies, Inc. Abstract Protein aggregation, where molecules assemble into dimers,

More information

2012 Waters Corporation 1

2012 Waters Corporation 1 UPLC User meeeting April 2012 Principles and Practices for SEC, IEX for Intact Protein Analysis by UPLC anders_feldthus@waters.com 2012 Waters Corporation 1 Agenda Ion-Exchange Chromatography Theory and

More information

Size-exclusion chromatography TT30 sample was analyzed using a Tosoh Haas TSK Gel G3000SW XL 7.8 mm 30cm column at 1 ml/min and 280 nm detection.

Size-exclusion chromatography TT30 sample was analyzed using a Tosoh Haas TSK Gel G3000SW XL 7.8 mm 30cm column at 1 ml/min and 280 nm detection. Analytical ultracentrifugation (AUC) and size exclusion chromatography (SEC-HPLC) were used to assess TT30 molecular weight distribution. The sedimentation distribution of TT30 is shown in Fig. S1A. The

More information

Formulation Development

Formulation Development Formulation Development Application Note NT-PR-013 Use of iformulate and nanodsf for Fast and Precise Protein Formulation Development Dennis Breitsprecher*, Rajiv Nayar #, *NanoTemper Technologies GmbH,

More information

Chromatography column for therapeutic protein analysis

Chromatography column for therapeutic protein analysis PRODUCT SPECIFICATIONS ProPac Elite WCX Column Chromatography column for therapeutic protein analysis Benefits Superior resolution power for proteins, monoclonal antibodies, and associated charge variants

More information

The Development of an Indirect Competitive. Immunomagnetic-Proximity Ligation Assay for Small-Molecule. Detection

The Development of an Indirect Competitive. Immunomagnetic-Proximity Ligation Assay for Small-Molecule. Detection The Development of an Indirect Competitive Immunomagnetic-Proximity Ligation Assay for Small-Molecule Detection Xuecheng Jiang, a Zhenhong Zhu, ab Zhihao Sun, a Luming Wang, a Lixiao Zhou, a Hanqiang Miao,

More information

Superdex 200 Increase columns

Superdex 200 Increase columns Data file 29-42-69 AC Size exclusion chromatography Superdex 2 Increase columns Superdex 2 Increase prepacked columns (Fig 1) are designed for size exclusion chromatography (SEC)/high resolution gel filtration

More information

Superdex 200 Increase columns

Superdex 200 Increase columns GE Healthcare Life Sciences Data file 29-452-69 AA Size exclusion chromatography Superdex 2 Increase columns Superdex 2 Increase prepacked columns (Fig 1) are designed for size exclusion chromatography

More information

STANDARD OPERATIONS PROCEDURES FOR THE COMMON FUND: PROTEIN CAPTURE REAGENTS PROGRAM (ELISA)

STANDARD OPERATIONS PROCEDURES FOR THE COMMON FUND: PROTEIN CAPTURE REAGENTS PROGRAM (ELISA) STANDARD OPERATIONS PROCEDURES FOR THE COMMON FUND: PROTEIN CAPTURE REAGENTS PROGRAM (ELISA) 1. PURPOSE This procedure is to be used for the characterization of purified monoclonal antibody. 2. SCOPE This

More information

Phenyl Membrane Adsorber for Bioprocessing

Phenyl Membrane Adsorber for Bioprocessing Phenyl Membrane Adsorber for Bioprocessing Sartobind Hydrophobic Interaction Membrane Chromatography The low substitution of the phenyl ligand on the membrane allows for mild elution of biomolecules such

More information

High-throughput screening and optimization of a multimodal polishing step in a monoclonal antibody purification process

High-throughput screening and optimization of a multimodal polishing step in a monoclonal antibody purification process GE Healthcare Application note 28-99- AB High-throughput process development High-throughput screening and optimization of a multimodal polishing step in a monoclonal antibody purification process Key

More information

Thermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis

Thermo Scientific MAbPac HIC Columns. Novel Hydrophobic Interaction HPLC Columns. Designed for Monoclonal Antibody Analysis Thermo Scientific MAbPac HIC Columns Novel Hydrophobic Interaction HPLC Columns Designed for Monoclonal Antibody Analysis Introduction The Thermo Scientific MAbPac HIC column family is designed for separations

More information

Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC

Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC Separate and Quantify Rituximab Aggregates and Fragments with High-Resolution SEC The Agilent 126 Infinity Bio-Inert Quaternary LC System and the AdvanceBio SEC 3Å, 2.7 µm Column Application Note Biologics

More information

R R Innovation Way P/N SECKIT-7830 Newark, DE 19711, USA Tel: Fax: Website: Published in November 2013

R R Innovation Way P/N SECKIT-7830 Newark, DE 19711, USA Tel: Fax: Website:  Published in November 2013 5-100 Innovation Way Newark, DE 19711, USA Tel:302-3661101 Fax:302-3661151 Website: www.sepax-tech.com Published in November 2013 P/N SECKIT-7830 These Phases are developed based on innovative surface

More information

A Fast and Robust Linear ph Gradient Separation Platform for Monoclonal Antibody (MAb) Charge Variant Analysis

A Fast and Robust Linear ph Gradient Separation Platform for Monoclonal Antibody (MAb) Charge Variant Analysis A Fast and Robust Linear ph Gradient Separation Platform for Monoclonal Antibody (MAb) Charge Variant Analysis Shanhua Lin, Julia Baek, and Chris Pohl Thermo Fisher Scientific, Sunnyvale, CA, USA Overview

More information

High-Throughput Glycan Screening to Remove Biopharmaceutical Development Bottlenecks

High-Throughput Glycan Screening to Remove Biopharmaceutical Development Bottlenecks High-Throughput Glycan Screening to Remove Biopharmaceutical Development Bottlenecks Mark Lies, Marcia Santos, and Tingting Li SCIEX Separations, Brea, CA Introduction Development of biopharmaceuticals

More information

Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs

Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs Charge Heterogeneity Analysis of Rituximab Innovator and Biosimilar mabs Application Note Author Suresh Babu C.V. Agilent Technologies India Pvt. Ltd, Bangalore, India Abstract This Application Note describes

More information

Suppl. Table I. Design of mutations within the BIIB4 and BIIB5 scfvs for screening in a thermal challenge assay.

Suppl. Table I. Design of mutations within the BIIB4 and BIIB5 scfvs for screening in a thermal challenge assay. Suppl. Table I. Design of mutations within the and scfvs for screening in a thermal challenge assay. scfv position (Kabat numbering) Residue Frequency a Covariation DEEK or Rosetta c scfv position (Kabat

More information

Formulation Aspects in Biosimilar Development. Kedar S. Gokhale, PhD. Lupin Ltd. (Biotech)

Formulation Aspects in Biosimilar Development. Kedar S. Gokhale, PhD. Lupin Ltd. (Biotech) Formulation Aspects in Biosimilar Development Kedar S. Gokhale, PhD. Lupin Ltd. (Biotech) Typical Protein Formulation Components of a protein formulation Active Ingredient Buffer Tonicity modifier Stabilizer

More information

Supporting Information

Supporting Information Supporting Information Chan et al. 10.1073/pnas.0903849106 SI Text Protein Purification. PCSK9 proteins were expressed either transiently in 2936E cells (1), or stably in HepG2 cells. Conditioned culture

More information

Method Development Considerations for Reversed-Phase Protein Separations

Method Development Considerations for Reversed-Phase Protein Separations Method Development Considerations for Reversed-Phase Protein Separations Hillary B. Hewitson, Thomas E. Wheat, Paula Hong, Kenneth J. Fountain APPLICATION BENEFITS n The BEH00 C 4 chemistry is available

More information

Rat / Mouse Amylin EIA Kit

Rat / Mouse Amylin EIA Kit Rat / Mouse Amylin EIA Kit Catalog No: IRAPKT2052 Lot No: SAMPLE INTENDED USE This Enzyme Immunoassay kit is designed to detect a specific peptide and its related peptides based on the principle of competitive

More information

Stability of sub-unit vaccines measured with the UNit label-free stability platform

Stability of sub-unit vaccines measured with the UNit label-free stability platform Application Note Stability of sub-unit vaccines measured with the UNit label-free stability platform Introduction Sub-unit vaccines and the need for adjuvants Of the many classes of vaccines that have

More information

Understanding the Effects of Common Mobile Phase Additives on the Performance of Size Exclusion Chromatography

Understanding the Effects of Common Mobile Phase Additives on the Performance of Size Exclusion Chromatography Understanding the Effects of Common Mobile Phase Additives on the Performance of Size Exclusion Chromatography 1 Presentation Importance of aggregate analysis in BioPharma manufacturing Analytical techniques

More information

Stability of Biopharmaceuticals: Past, Present and Future. Paul Varley, Vice President, Biopharmaceutical Development

Stability of Biopharmaceuticals: Past, Present and Future. Paul Varley, Vice President, Biopharmaceutical Development Stability of Biopharmaceuticals: Past, Present and Future Paul Varley, Vice President, Biopharmaceutical Development Agenda 1 The last 20 years or so 2 Where we are now 3 The future 2 Early Process - THEN

More information

Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility

Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility Agilent AdvanceBio SEC Columns for Aggregate Analysis: Instrument Compatibility Technical Overview Introduction Agilent AdvanceBio SEC columns are a new family of size exclusion chromatography (SEC) columns

More information

The goal of formulation

The goal of formulation B i o P r o c e s s TECHNICAL Author Insights Online Exclusive http://bit.ly/bpi-author-abs Development of a High-Throughput Formulation Screening Platform for Monoclonal Antibodies Paul Casaz, Anna Brousseau,

More information

Seamless Method Transfer from an Agilent 1260 Infinity Bio-inert LC to an Agilent 1260 Infinity II Bio-inert LC

Seamless Method Transfer from an Agilent 1260 Infinity Bio-inert LC to an Agilent 1260 Infinity II Bio-inert LC Seamless Method Transfer from an Agilent 1 Infinity Bio-inert LC to an Agilent 1 Infinity II Bio-inert LC Charge Variant Analysis of Rituximab Innovator and Biosimilar Application Note Biologics & Biosimilars

More information

Size Exclusion BioHPLC Columns

Size Exclusion BioHPLC Columns Size Exclusion BioHPLC Columns Size Exclusion Product Families Particle Porosity Functionalities Particle Pore Size Application Sizes Agilent Bio SEC- Silica Fully porous N/A um 00A, 0A, 00A High efficiency

More information

Phenyl Membrane Adsorber for Bioprocessing

Phenyl Membrane Adsorber for Bioprocessing Phenyl Membrane Adsorber for Bioprocessing Sartobind Hydrophobic Interaction Membrane Chromatography The low substitution of the phenyl ligand on the membrane allows for mild elution of biomolecules such

More information

An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite

An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite An effective platform for purification of IgM monoclonal antibodies using Hydroxyapatite Frank Hensel, Patrys, GmbH Pete Gagnon, Validated Biosystems 5th International Conference on Hydroxyapatite and

More information

3. Close the bottom end of the column and apply the packing device on top. Pump water through the upper adaptor to remove air.

3. Close the bottom end of the column and apply the packing device on top. Pump water through the upper adaptor to remove air. INSTRUCTIONS FOR USE WorkBeads Protein A Product name Pack size Article number WorkBeads Protein A Bulk Media 1.5 ml 40605001 Bulk Media 5 ml 40605002 Bulk Media 10 ml 40605003 Bulk Media 100 ml 40605004

More information

CX-1 ph Gradient Buffer

CX-1 ph Gradient Buffer User Manual CX-1 ph Gradient Buffer 065534 Revision 03 May 2016 For Research Use Only. Not for use in diagnostic procedures. Product Manual for CX-1 ph Gradient Buffer A (ph 5.6) (125 ml P/N: 083273) (250

More information

Biochemical Binding ADCC Assays Utilizing LANCE Toolbox Reagents for the Characterization of higgs and FcγR1A

Biochemical Binding ADCC Assays Utilizing LANCE Toolbox Reagents for the Characterization of higgs and FcγR1A APPLICATION NOTE LANCE TR-FRET Author: Daniel Cardillo PerkinElmer, Inc. Hopkinton, MA Biochemical Binding ADCC Assays Utilizing LANCE Toolbox Reagents for the Characterization of higgs and FcγR1A Introduction

More information

Nonionic Polymer Enhancement of Aggregate Removal in Ion Exchange

Nonionic Polymer Enhancement of Aggregate Removal in Ion Exchange Nonionic Polymer Enhancement of Aggregate Removal in Ion Exchange and Hydroxyapatite Chromatography Pete Gagnon, Richard Richieri, Simin Zaidi 12th Annual Waterside Conference, San Juan, Puerto Rico, April

More information

Rapid UHPLC Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) 300SB-C8 Column

Rapid UHPLC Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) 300SB-C8 Column Rapid UHP Analysis of Reduced Monoclonal Antibodies using an Agilent ZORBAX Rapid Resolution High Definition (RRHD) 3SB-C8 Column Application Note BioPharma Authors James Martosella, Phu Duong, Susanne

More information

HIC as a Complementary, Confirmatory Tool to SEC for the Analysis of mab Aggregates

HIC as a Complementary, Confirmatory Tool to SEC for the Analysis of mab Aggregates HIC as a Complementary, Confirmatory Tool to SEC for the Analysis of mab Aggregates Julia Baek, Shanhua Lin, Xiaodong Liu, Thermo Fisher Scientific, Sunnyvale, CA Application Note 2126 Key Words Size exclusion

More information

Tools and solutions for separation of charged mab variants

Tools and solutions for separation of charged mab variants GE Healthcare Tools and solutions for separation of charged mab variants A biosimilar is an almost identical version of an originator product, but to attain regulatory approval, a comparable quality to

More information

Comparison of Different Brands of Carrier Ampholytes for Monoclonal Antibody Charge Heterogeneity Analysis by Capillary Isoelectric Focusing

Comparison of Different Brands of Carrier Ampholytes for Monoclonal Antibody Charge Heterogeneity Analysis by Capillary Isoelectric Focusing Comparison of Different Brands of Carrier Ampholytes for Monoclonal Antibody Charge Heterogeneity Analysis by Capillary Isoelectric Focusing Application Note Biotherapeutics & Biosimilars Author Christian

More information

A universal chromatography method for aggregate analysis of monoclonal antibodies

A universal chromatography method for aggregate analysis of monoclonal antibodies APPLICATION NOTE A universal chromatography method for aggregate analysis of monoclonal antibodies No. 2161 Amy Farrell 1, Jonathan Bones 1, and Ken Cook 2 1 NIBRT, Dublin, Ireland; 2 Thermo Fisher Scientific,

More information

Use of ITC/DSC for the studies of biomolecularstability and interaction of excipients with proteins. Natalia Markova

Use of ITC/DSC for the studies of biomolecularstability and interaction of excipients with proteins. Natalia Markova Use of ITC/DSC for the studies of biomolecularstability and interaction of excipients with proteins Natalia Markova MIBio2012 Outline Brief intro to the specifics of protein stability profiling and optimization

More information

Size Exclusion BioHPLC columns Ion Exchange BioHPLC columns

Size Exclusion BioHPLC columns Ion Exchange BioHPLC columns Confidently separate and characterize bio-molecules with Agilent BioHPLC columns Size Exclusion BioHPLC columns Ion Exchange BioHPLC columns "It's a struggle to isolate and identify charge variants of

More information

Value of DSC in characterization and optimization of protein stability as compared to other thermal stability assays

Value of DSC in characterization and optimization of protein stability as compared to other thermal stability assays Value of DSC in characterization and optimization of protein stability as compared to other thermal stability assays 韩佩韦 Malvern Instruments 2016.02.28 Complex task of characterization and optimization

More information

Sean M. McCarthy and Martin Gilar Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL RESULTS AND DISCUSSION

Sean M. McCarthy and Martin Gilar Waters Corporation, Milford, MA, U.S. INTRODUCTION EXPERIMENTAL RESULTS AND DISCUSSION UPLC Separation of DNA Duplexes Sean M. McCarthy and Martin Gilar Waters Corporation, Milford, MA, U.S. INTRODUCTION Over the past 2 years there has been a considerable amount of effort focused on the

More information

Electric Supplement Information

Electric Supplement Information Electric Supplement Information Preparation of DNA-AuNPs Thiol-modified oligonucleotide (5 -Cy5- ATCTCGGCTCTGCTAGCGAAAAAAAAAA-(C3H6)-SH-3, 5 15.5 OD) was added to 13 nm citrate-stabilized AuNPs (~3 nmol

More information

Protein Separation with ph Gradients Using Composite Buffer Systems Calculated by the Agilent Buffer Advisor Software

Protein Separation with ph Gradients Using Composite Buffer Systems Calculated by the Agilent Buffer Advisor Software Protein Separation with ph Gradients Using Composite Buffer Systems Calculated by the Agilent Buffer Advisor Software Technical Overview. Author Sonja Schneider Agilent Technologies, Inc. Waldbronn, Germany

More information

Biosensing Probe for Quality Control Monitoring of the Structural Integrity of Therapeutic Antibodies

Biosensing Probe for Quality Control Monitoring of the Structural Integrity of Therapeutic Antibodies Supporting Information Biosensing Probe for Quality Control Monitoring of the Structural Integrity of Therapeutic Antibodies Hideki Watanabe, Seiki Yageta, Hiroshi Imamura, and Shinya Honda *,, Biomedical

More information

Recent improvements in the use of CHT TM ceramic hydroxyapatite for removal of aggregates from monoclonal Antibodies

Recent improvements in the use of CHT TM ceramic hydroxyapatite for removal of aggregates from monoclonal Antibodies Recent improvements in the use of CHT TM ceramic hydroxyapatite for removal of aggregates from monoclonal Antibodies Pete Gagnon Validated Biosystems February 28, 2007 Why use CHT for MAb Purification?

More information

Forced Degradation of Protein Therapeutics

Forced Degradation of Protein Therapeutics Forced Degradation of Protein Therapeutics Wim Jiskoot Division of Drug Delivery Technology Leiden Academic Centre for Drug Research (LACDR) AAPS Annual Meeting Orlando, FL 28 October 2015 Forced degradation

More information

Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column

Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb 5 µm Column Analysis of Intact and C-terminal Digested IgG1 on an Agilent Bio MAb µm Column Application Note BioPharma Authors Xiaomi Xu and Phu T Duong Agilent Technologies, Inc. Abstract Nearly all proteins undergo

More information

EAG.COM MATERIALS SCIENCES APPLICATION NOTE. By J. Tompkins 1, T. Spurgeon 1, R. Tobias 1, J. Anders 1, E. Butler-Roberts 2, and M.

EAG.COM MATERIALS SCIENCES APPLICATION NOTE. By J. Tompkins 1, T. Spurgeon 1, R. Tobias 1, J. Anders 1, E. Butler-Roberts 2, and M. MATERIALS SCIENCES NOW WHETHER THE LINER IS THE PROBLEM? HOW DO YOU EVALUATE HYDROPHOBIC COMPOUNDS BY SPME? HOW DO YOU COMPARE FEEDSTOCK SUPPLIERS? O YOU COMPLY WITH ? HOW DO YOU ADDRESS AN

More information

Generating Automated and Efficient LC/MS Peptide Mapping Results with the Biopharmaceutical Platform Solution with UNIFI

Generating Automated and Efficient LC/MS Peptide Mapping Results with the Biopharmaceutical Platform Solution with UNIFI with the Biopharmaceutical Platform Solution with UNIFI Vera B. Ivleva, Ying Qing Yu, Scott Berger, and Weibin Chen Waters Corporation, Milford, MA, USA A P P L I C AT ION B E N E F I T S The ability to

More information

Application Note. Biopharma. Authors. Abstract. James Martosella, Phu Duong Agilent Technologies, Inc Centreville Rd Wilmington, DE 19808

Application Note. Biopharma. Authors. Abstract. James Martosella, Phu Duong Agilent Technologies, Inc Centreville Rd Wilmington, DE 19808 Reversed-Phase Optimization for Ultra Fast Profiling of Intact and Reduced Monoclonal Antibodies using Agilent ZORBAX Rapid Resolution High Definition 3SB-C3 Column Application Note Biopharma Authors James

More information

Columns for Biomolecules BioLC Column Lines

Columns for Biomolecules BioLC Column Lines Columns for Biomolecules BioLC Column Lines Monoclonal Antibodies Glycans GlycanPac Nucleic Acids DNAPac Protein A Accucore Amide-HILIC DNAPac PA1 SEC-1 GlycanPac AXH-1 DNAPac PA2 SCX-1 GlycanPac AXR-1

More information

Automated Chemical Denaturation as a Tool to Evaluate Protein Stability and Optimize the Formulation of Biologics

Automated Chemical Denaturation as a Tool to Evaluate Protein Stability and Optimize the Formulation of Biologics Automated Chemical Denaturation as a Tool to Evaluate Protein Stability and Optimize the Formulation of Biologics Ernesto Freire Johns Hopkins University Baltimore, MD 21218 ef@jhu.edu AVIA 2304 Automated

More information

LightCycler 480 Instrument Quick Guide Protein Melting

LightCycler 480 Instrument Quick Guide Protein Melting LightCycler 480 Instrument Quick Guide Protein Melting Protein Melting Analysis Principle: Protein Melting is monitored using hydrophobic binding dyes, like SYPRO Orange, and is used to determine the stability

More information

BACTERIAL PRODUCTION EXPRESSION METHOD OVERVIEW: PEF # GENE NAME EXPRESSION VECTOR MOLECULAR WEIGHT kda (full-length) 34.

BACTERIAL PRODUCTION EXPRESSION METHOD OVERVIEW: PEF # GENE NAME EXPRESSION VECTOR MOLECULAR WEIGHT kda (full-length) 34. BACTERIAL PRODUCTION PEF # GENE NAME EXPRESSION VECTOR MOLECULAR WEIGHT 2015-XXXX XXXX pet-32a 50.9 kda (full-length) 34.0 kda (cleaved) EXPRESSION METHOD OVERVIEW: Plasmid DNA was transformed into BL21

More information

Development of High Concentration cetuximab Formulations using Ultrafiltration and Precipitation Techniques

Development of High Concentration cetuximab Formulations using Ultrafiltration and Precipitation Techniques Dissertation zur Erlangung des Doktorgrades der Fakultat fur Chemie und Pharmazie der Ludwig-Maximilians-Universitat Munchen Development of High Concentration cetuximab Formulations using Ultrafiltration

More information

Analysis of biomolecules by SEC and Ion-Exchange UPLC

Analysis of biomolecules by SEC and Ion-Exchange UPLC Analysis of biomolecules by SEC and Ion-Exchange UPLC Anders Feldthus, Waters Nordic 2011 Waters Corporation 1 Waters Commitment To develop, commercialize and market columns that when used on Waters ACQUITY

More information

PRODUCT DATA SHEET. Carboxylated Fluorescent Gold Nanoparticles. Description. Characteristics

PRODUCT DATA SHEET. Carboxylated Fluorescent Gold Nanoparticles. Description. Characteristics PRODUCT DATA SHEET Carboxylated Fluorescent Gold Nanoparticles Description Cytodiagnostics carboxylated fluorescent gold nanoparticles is a unique product that combines our Cyto fluorescent dyes and gold

More information

Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3

Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3 Separation of Recombinant Human Erythropoietin (repo) Using Agilent Bio SEC-3 Application Note BioPharma Authors Phu T Duong and James Martosella Agilent Technologies, Inc. 285 Centerville Rd, Wilmington,

More information

CONSEQUENCES OF SAMPLE AGE ON BIOTHERAPEUTIC HIGHER ORDER STRUCTURE: INSIGHTS FROM NATIVE ION MOBILITY-MASS SPECTROMETRY METHODS

CONSEQUENCES OF SAMPLE AGE ON BIOTHERAPEUTIC HIGHER ORDER STRUCTURE: INSIGHTS FROM NATIVE ION MOBILITY-MASS SPECTROMETRY METHODS COSEQUECES OF SAMPLE AGE O BIOTHERAPEUTIC HIGHER ORDER STRUCTURE: ISIGHTS FROM ATIVE IO MOBILITY-MASS SPECTROMETRY METHODS Richard Kerr ORISE Post-Doctoral Fellow US FDA, Division of Pharmaceutical Analysis

More information

phab Amine and Thiol Reactive Dyes

phab Amine and Thiol Reactive Dyes TECHNICAL MANUAL phab Amine and Thiol Reactive Dyes Instructions for Use of Products G9831, G9835, G9841 and G9845 Revised 12/17 TM451 phab Amine and Thiol Reactive Dyes All technical literature is available

More information

TOYOPEARL GigaCap Series

TOYOPEARL GigaCap Series TOYOPEARL GigaCap Series INTRODUCTION Ion Exchange Chromatography (IEC) is one of the most frequently used chromatographic modes for the separation and purification of biomolecules. Compared with other

More information

Structural bases for N-glycan processing by mannosidephosphorylase

Structural bases for N-glycan processing by mannosidephosphorylase Supporting information Volume 71 (2015) Supporting information for article: Structural bases for N-glycan processing by mannosidephosphorylase Simon Ladevèze, Gianluca Cioci, Pierre Roblin, Lionel Mourey,

More information

Higher Order mab Aggregate Analysis using New Innovative SEC Technology

Higher Order mab Aggregate Analysis using New Innovative SEC Technology Higher Order mab Aggregate Analysis using New Innovative SEC Technology Ronald E. Majors, Ph.D. LCGC No. America West Chester, PA USA WCBP 2016 Washington, DC Linda Lloyd, Ph.D. Agilent Technologies Church

More information

User Manual. Cat. No

User Manual. Cat. No User Manual ELISA Amplification System Cat. No. 19589-019 Table of Contents 1. Notices to Customer... 1 1.1 Important Information... 1 1.2 Precautions... 1 2. Overview... 2 3. Methods... 4 3.1 Components...

More information